Corindus Vascular Robotics Inc
Corindus Vascular Robotics — Investor Presentation (November 2017)
16 slides from Corindus Vascular Robotics's investor presentation, Nov 9, 2017
Slide 1: Precision Vascular Robotics
1 Precision Vascular Robotics Corindus Vascular Robotics (CVRS) November 2017
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains “forward - looking statements” (as such term is defined in section 27 a of the securities act of 1933 , as amended, and section 21 e of the securities exchange act of 1934 , as amended), and information relating to the company, that are based on
Slide 3: Corindus Today: A leader in vascular robotics
Corindus Today A leader in vascular robotics LARGE Market Opportunity with Long GROWTH Runway $4.5B 1 market opportunity in 2018 driven by over 2.5 million coronary and 3 million non - coronary procedures performed per year DIFFERENTIATED Technology ONLY FDA cleared robotic platform for percutaneous
Slide 4: Large & growing worldwide market opportunity
1 Market opportunity assessment based on market research reports and Corindus estimate 2 Peripheral Vascular includes lower limb, carotid, renal, iliac and AAA (abdominal aortic aneurysm) procedures 3 Millennium Research Group Interventional Market Opportunity Large & growing worldwide market • $4.5
Slide 5: Market Drivers
Market Drivers 5 Corindus poised for growth in PCI robotics market FAVORABLE PATIENT DEMOGRAPHICS SHORTAGE OF DOCTORS DISRUPTIVE TECHNOLOGY CONTINUED GROWTH OF PCI PROCEDURES WORLDWIDE
Slide 6: Company Milestones
Company Milestones 6 Next Generation CorPath GRX cleared by FDA with Guide Catheter Control and Enhanced User Interface CorPath GRX seeing high utilization in cath labs & 2x increase in adoption with existing customers Adoption Global Signed Distribution Agreement with #2 company in Japan (Mitsubish
Slide 7: Traditional PCI vs CorPath Robotic PCI
Struggle to see angiography Assess Anatomy Close proximity ergonomic visualization Trial & error, wire spinning Navigate Precise ‘Point & Shoot’ predictability ‘Eyeball’ estimate Measure Anatomy Robotic - assisted sub - mm Measurement Manual adjustment Position Stent 1mm precise positioning Devices
Slide 8: Why Vascular Robotics
Why Vascular Robotics 8 Benefits for patients, physicians, & hospitals DIFFERENTIATION • Position hospital on the cutting edge by deploying robotics as part of a hi - tech cardiology model • Clinical leadership • Attract & retain physicians PATIENT BENEFIT • Robotic precision to reduce stent utiliza
Slide 9: Evolution of Interventional Treatment
Evolution of Interventional Treatment 9 Hi - tech cardiology model with robotics Occupational Hazards High risk working environment Physician burnout Traditional PCI Stagnant Market Competition for market share Radial adoption slow Precise Treatment Precise robotic movement Enhanced visualization Mu
Slide 10: Telestenting First-in-Human Study
Telestenting First - in - Human Study Study showed 86.4% technical success and 95% procedural success 10 REMOTE - PCI REMOTE - PCI Study explored feasibility of remote telestenting using a robotic system Single - center prospective observational study performed at Spectrum Health, Grand Rapids, MI 2
Slide 11: Vascular Robotic Clinical Roadmap
Vascular Robotic Clinical Roadmap Demonstrating excellence in multiple lesion types and anatomies Product Evolution Robotic system capability Exploratory Feasibility Expand Use NEURO PERIPHERAL PCI 11 CorPath 200 and CorPath GRX Systems are indicated for PCI. Only the CorPath 200 System is indicated
Slide 12: Clinical Leadership
Clinical Leadership 12 J. Aaron Grantham, MD Saint Luke's Hospital of Kansas City Marty Leon, MD NewYork - Presbyterian Hospital Louis Cannon, MD BioStar Ventures Campbell Rogers, MD HeartFlow Steven Almany, MD Beaumont Hospital David Kandzari, MD Piedmont Heart Bill Lombardi, MD University of Washi
Slide 13: Corindus Tomorrow
Corindus Tomorrow 13 Growth in PCI Increasing penetration of robotics globally; growing body of clinical research Collaborating on device integration to advance hi - tech cardiology model, partnering to deliver medical education programs New Partnerships Expanded Capabilities First Automated Movemen
Slide 14: Strategic Objectives
14 Corindus Vascular Robotics Strategic Objectives Near Term Mid to Long Term Mid to Long Term x Recurring revenue streams and NG3 system launch x Expansion into additional disease states (neurovascular and structural heart) x Global expansion and remote tele - proctoring x Establish at least 25 new
Slide 15: Financial Snapshot
1 As of September 30, 2017 2 Outstanding principal balance Financial Snapshot Key Financial Metrics Cash and Cash Equivalents 1 $26.2 million Debt 1,2 $250,000 15
Slide 16: About Corindus Vascular Robotics
Corindus Vascular Robotics, Inc. is a global technology leader in robotic - assisted vascular interventions. The company's CorPath ® System is the first FDA - cleared medical device to bring robotic - assisted precision to percutaneous coronary interventions. With the CorPath System, Corindus Vascul
Corindus Vascular Robotics — Investor Presentation (November 2017) on 6ix